Consortium of Multiple Sclerosis Centers Annual Meeting (CMSC)

A new study reveals higher rates of postpartum depression in women with multiple sclerosis, emphasizing the need for early screening and management strategies.

A recent analysis highlights the increasing use of Octave's MSDA test in managing multiple sclerosis, showcasing its impact on treatment decisions and disease monitoring.

Gabrielle Macaron, MD, assistant professor of neuroscience at Université de Montréal, discussed the nuanced clinical decision-making involved in initiating a DMT for patients newly diagnosed with MS.

At CMSC 2025, Cassandra Moore, MPH, CPH, associate vice president of strategy and innovation at the National MS Society, discussed the impact of health and wellness coaching in patients with multiple sclerosis.

The assistant professor in the Department of Neuroscience at Université de Montréal discussed the importance of weighing the risks of multiple sclerosis against treatment risks, emphasizing individualized care. [WATCH TIME: 4 minutes]

The associate vice president of strategy and innovation at the National MS Society highlighted the measurable benefits of health and wellness coaching for individuals with multiple sclerosis. [WATCH TIME: 5 minutes]

The director of the John A. Schafer, MD Multiple Sclerosis Achievement Center at Dignity Health discussed the effect of loneliness and social isolation on individuals living with multiple sclerosis.

The assistant professor of neurology at the Medical College of Wisconsin talked about the complexities of advanced multiple sclerosis, highlighting gaps in clinical trials and the need for individualized care strategies. [WATCH TIME: 3 minutes]

Sam Hooshmand, DO, assistant professor of neurology at the Medical College of Wisconsin, discussed the complexities of defining, diagnosing, and managing advanced MS.

Ahmed Abdelhak, MD, assistant professor of neurology at the UCSF, discussed the evolving landscape of biomarkers in multiple sclerosis and their potential to transform remyelination approaches.

The executive director of The Sumaira Foundation discussed a newly funded international trial assessing both approved and off-label NMOSD therapies to better inform treatment decisions and patient care. [WATCH TIME: 2 minutes]

The director of the John A. Schafer, MD Multiple Sclerosis Achievement Center at Dignity Health highlighted the significant impact of loneliness in individuals with multiple sclerosis. [WATCH TIME: 6 minutes]

The assistant professor of neurology at the University of California, San Francisco discussed current advancements and ongoing challenges in identifying biomarkers to accurately monitor remyelination in MS clinical trials. [WATCH TIME: 5 minutes]

The assistant professor of neurology at Mayo Clinic College of Medicine and Science outlined a case of myelin oligodendrocyte glycoprotein antibody-associated disease from diagnosis to long-term management. [WATCH TIME: 5 minutes]

The associate vice president of research at National MS Society talked about the need for evidence-based wellness strategies in multiple sclerosis, particularly focusing on psychosocial interventions.

Findings from a late-breaking poster presented at CMSC 2025 suggest that CBT does not improve fatigue severity or impact in patients with multiple sclerosis.

The assistant professor in the Department of Neuroscience at Université de Montréal discussed key clinical factors influencing DMT selection in patients newly diagnosed with multiple sclerosis. [WATCH TIME: 5 minutes]

Recent analysis confirms cladribine's safety for multiple sclerosis, showing no increased pregnancy risks and effective long-term outcomes in patients.

New long-term data reveals ponesimod's effectiveness in reducing relapses and MRI lesions in relapsing multiple sclerosis patients, ensuring safety over 8.2 years.

Neurologists advocate for personalized treatment approaches in older MS patients, emphasizing the importance of individual assessment over age-based rules for DMT discontinuation.

The professor of pediatrics in neurology at the University of Toronto discussed differences in disease course, treatment strategy, and trial challenges of MOG-associated disorders in pediatric versus adult patients. [WATCH TIME: 5 minutes]

Fenebrutinib shows promising results in reducing relapse rates and disability progression in relapsing multiple sclerosis patients over two years.

The assistant professor of neurology at Barrow Neurological Institute talked about the lack of public awareness for hypertension among individuals with MS despite many meeting diagnostic criteria. [WATCH TIME: 6 minutes]

Cladribine shows promising results in reducing relapse rates for patients with relapsing multiple sclerosis after inadequate response to injectable therapies.

The associate professor of medicine at the Cleveland Clinic Lerner College of Medicine highlighted the importance of early, multidisciplinary intervention for patients with multiple sclerosis. [WATCH TIME: 3 minutes]

Host Jeffrey Wilken, PhD, chats with Riley Bove, MD, about the third day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.

A newly presented analysis of data from the Novartis Global Safety Database and the PRIM study assessed pregnancy and infant outcomes in women with multiple sclerosis treated with ofatumumab.

The vice chair of neurology at the Hospital Clínico San Carlos in Madrid highlighted the growing importance of detecting and managing progression in multiple sclerosis, particularly PIRA. [WATCH TIME: 6 minutes]